<DOC>
	<DOCNO>NCT00002987</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . Combining radiation therapy chemotherapy may kill tumor cell . PURPOSE : Randomized phase III trial compare effectiveness combination chemotherapy plus radiation therapy radiation therapy alone treat patient early-stage Hodgkin 's disease .</brief_summary>
	<brief_title>Combination Chemotherapy Given With Radiation Therapy Radiation Therapy Alone Treating Patients With Early-Stage Hodgkin 's Disease</brief_title>
	<detailed_description>OBJECTIVES : I . Determine recurrence rate long term survival patient early stage Hodgkin 's disease give vincristine/doxorubicin/prednisolone/ etoposide/cyclophosphamide/bleomycin ( VAPEC-B ) chemotherapy involve field radiation v mantle radiotherapy . OUTLINE : This randomize multicenter study . Patients randomize receive either vincristine/doxorubicin/prednisolone/etoposide/cyclophosphamide/ bleomycin ( VAPEC-B ) chemotherapy involve field radiotherapy mantle radiotherapy . Patients receive VAPEC-B give prednisolone daily week 1-6 , doxorubicin IV along cyclophosphamide IV week 1 , doxorubicin IV etoposide orally 5 day week 3 , vincristine bleomycin IV week 2 4 . Involved field radiotherapy commence week 6 , within 14 21 day last chemotherapy treatment . Patients randomize receive mantle radiotherapy give treatment daily 4 week . Patients follow every 3 month first two year , every 4 month third year , every 6 month fourth fifth year annually thereafter . PROJECTED ACCRUAL : 400 patient accrue 4-5 year .</detailed_description>
	<mesh_term>Hodgkin Disease</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Etoposide</mesh_term>
	<mesh_term>Bleomycin</mesh_term>
	<mesh_term>Vincristine</mesh_term>
	<mesh_term>Prednisolone</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically proven stage IA IIA Hodgkin 's disease without mediastinal bulk Patients Hodgkin 's disease exist diaphragm eligible PATIENT CHARACTERISTICS : Age : 16 75 Performance status : Not specify Life expectancy : Not specify Hematopoietic : Not specify Hepatic : Not specify Renal : Not specify Other : Not HIV positive No prior malignancy basal cell carcinoma cervical intraepithelial neoplasia PRIOR CONCURRENT THERAPY : No prior treatment</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>March 2005</verification_date>
	<keyword>stage I adult Hodgkin lymphoma</keyword>
	<keyword>stage II adult Hodgkin lymphoma</keyword>
</DOC>